Recent News

• 05.11.2026 - Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results
• 05.07.2026 - Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast
• 05.07.2026 - Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.
• 04.28.2026 - Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
• 03.06.2026 - Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
• 02.25.2026 - Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Recent Filings

• 05.11.2026 - 8-K Current report
• 05.11.2026 - EX-99.1 EX-99.1
• 05.11.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.08.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.07.2026 - EX-99.1 EX-99.1
• 05.07.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.07.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 05.07.2026 - 8-K Current report
• 04.30.2026 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.26.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors